Cyclin D–cyclin-dependent kinase 4 (CDK4) or CDK6 activation promotes cell cycle progression through the phosphorylation of substrates, including RB and transcription factors with roles in ...

The third chapter places cyclin D-dependent kinases at the center of cellular signaling networks and considers the complexity of cross-talk between pathways within the network. Building on this ...

Initially, a mitogenic stimulus leads to the upregulation of cyclin D gene expression, which binds to CDK4. Retinoblastoma protein (Rb) usually functions to inhibit the transcription factor E2F ...

One of the most well studied is the retinoblastoma tumour suppressor (Rb). Cyclin D bound to CDK4/6 phosphorylates this Rb protein, which usually inhibits transcription factor E2F. Therefore ...

Patients are grouped according to high or low total cyclin E levels (Panels A and D), and the presence or absence of cyclin D1 (Panels B and E) or cyclin D3 (Panels C and F), as determined by ...

One major focus of Dr. Diehl’s research concerns the mechanisms whereby growth-signaling pathways regulate the cyclin D/CDK4/6 kinases and from this, the identification of therapeutic vulnerabilities.

Circle Pharma to present late-breaking poster at AACR highlighting new mechanistic insights into the anti-cancer activity of cyclin A/B RxL ... and Pablo D. Garcia, Circle Pharma Inc., South ...

A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors. Background: PD 0332991 is a potent, oral, ...

Patients at least 18 years old with solid tumors or hematologic malignancies with CDK4/6 mutations or amplifications, cyclin-D1/D3 gene amplifications, or p16 gene mutations or loss were enrolled.